Looking for classes? Ksquare Career Institute, Bengaluru →
The first clinical gene therapy was given for treating
A
Adenosine deaminase deficiency
B
Diabetes mellitus
C
Chicken pox
D
Rheumatoid arthritis
Detailed Solution
The first clinical gene therapy was given in 1990 to a 4-year-old girl suffering from adenosine deaminase (ADA) deficiency.
ADA is an enzyme essential for the functioning of the immune system; the disorder is caused by deletion of the ADA gene.
Lymphocytes from the patient's blood were grown in culture, a functional ADA cDNA was introduced into them using a retroviral vector, and the cells were returned to the patient.
Diabetes mellitus is treated with insulin, chicken pox is a viral infection and rheumatoid arthritis is an auto-immune disorder; none of them was the first target of gene therapy.
Hence the first clinical gene therapy was for adenosine deaminase deficiency.
ADA is an enzyme essential for the functioning of the immune system; the disorder is caused by deletion of the ADA gene.
Lymphocytes from the patient's blood were grown in culture, a functional ADA cDNA was introduced into them using a retroviral vector, and the cells were returned to the patient.
Diabetes mellitus is treated with insulin, chicken pox is a viral infection and rheumatoid arthritis is an auto-immune disorder; none of them was the first target of gene therapy.
Hence the first clinical gene therapy was for adenosine deaminase deficiency.